180 related articles for article (PubMed ID: 10579080)
1. Neo-adjuvant and adjuvant treatment of locally invasive bladder cancer.
Schultz-Lampel D; Lampel A
Curr Opin Urol; 1999 Sep; 9(5):419-24. PubMed ID: 10579080
[TBL] [Abstract][Full Text] [Related]
2. Radical cystectomy with or without adjuvant polychemotherapy for non-organ-confined transitional cell carcinoma of the urinary bladder: prognostic impact of lymph node involvement.
Stöckle M; Wellek S; Meyenburg W; Voges GE; Fischer U; Gertenbach U; Thüroff JW; Huber C; Hohenfellner R
Urology; 1996 Dec; 48(6):868-75. PubMed ID: 8973669
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience.
Stöckle M; Meyenburg W; Wellek S; Voges GE; Rossmann M; Gertenbach U; Thüroff JW; Huber C; Hohenfellner R
J Urol; 1995 Jan; 153(1):47-52. PubMed ID: 7966789
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant chemotherapy for deep muscle-invasive transitional cell bladder carcinoma - a practice guideline.
Segal R; Winquist E; Lukka H; Chin JL; Brundage M; Markman BR;
Can J Urol; 2002 Oct; 9(5):1625-33. PubMed ID: 12431323
[TBL] [Abstract][Full Text] [Related]
5. Results of radical cystectomy for transitional cell carcinoma of the bladder and the effect of chemotherapy.
Soloway MS; Lopez AE; Patel J; Lu Y
Cancer; 1994 Apr; 73(7):1926-31. PubMed ID: 8137219
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant and neoadjuvant chemotherapy for invasive bladder cancer.
Kuroda M; Meguro N; Maeda O; Saiki S; Kinouchi T; Usami M; Kotake T
Cancer Chemother Pharmacol; 1994; 35 Suppl():S9-13. PubMed ID: 7527736
[TBL] [Abstract][Full Text] [Related]
7. Neo-adjuvant chemotherapy and bladder preservation in locally advanced transitional cell carcinoma of the bladder.
Benson MC
Ann Oncol; 1999 Nov; 10(11):1269-70. PubMed ID: 10631452
[No Abstract] [Full Text] [Related]
8. The role of adjuvant chemotherapy for locally advanced bladder cancer.
Lehmann J; Retz M; Stöckle M
World J Urol; 2001 Apr; 19(2):133-40. PubMed ID: 11374316
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
George L; Bladou F; Bardou VJ; Gravis G; Tallet A; Alzieu C; Serment G; Salem N
Urology; 2004 Sep; 64(3):488-93. PubMed ID: 15351577
[TBL] [Abstract][Full Text] [Related]
10. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder.
Blick C; Hall P; Pwint T; Al-Terkait F; Crew J; Powles T; Macaulay V; Munro N; Douglas D; Kilbey N; Protheroe A; Chester JD
Cancer; 2012 Aug; 118(16):3920-7. PubMed ID: 22614698
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant chemotherapy for invasive urothelial cancer: experience with a methotrexate, vincristine, cisplatin, cyclophosphamide, adriamycin and bleomycin (MVP-CAB) regimen: a preliminary report.
Gohji K; Higuchi A; Maruyama S; Minayoshi K; Fujii A; Itoh N; Hasunuma Y; Tanaka H; Izumi T
Jpn J Clin Oncol; 1993 Oct; 23(5):291-8. PubMed ID: 7693990
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy of advanced transitional-cell carcinoma of the bladder.
Miller RS; Torti FM
Cancer Chemother Pharmacol; 1992; 30 Suppl():S99-110. PubMed ID: 1394829
[TBL] [Abstract][Full Text] [Related]
13. [Neoadjuvant and adjuvant chemotherapy of bladder cancer].
Kuroda M; Kotake T
Gan To Kagaku Ryoho; 1994 Oct; 21 Suppl 3():362-9. PubMed ID: 7986116
[TBL] [Abstract][Full Text] [Related]
14. Primary cisplatin, methotrexate and vinblastine aiming at bladder preservation in invasive bladder cancer: multivariate analysis on prognostic factors.
Angulo JC; Sanchez-Chapado M; Lopez JI; Flores N
J Urol; 1996 Jun; 155(6):1897-902. PubMed ID: 8618282
[TBL] [Abstract][Full Text] [Related]
15. RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy.
Hagan MP; Winter KA; Kaufman DS; Wajsman Z; Zietman AL; Heney NM; Toonkel LM; Jones CU; Roberts JD; Shipley WU
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):665-72. PubMed ID: 14529770
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant chemotherapy for invasive bladder carcinoma: disease outcome and bladder preservation and relationship to local tumor response.
Hatcher PA; Hahn RG; Richardson RL; Zincke H
Eur Urol; 1994; 25(3):209-15. PubMed ID: 8200403
[TBL] [Abstract][Full Text] [Related]
17. Adjunctive adjuvant or neoadjuvant chemotherapy for locally advanced bladder cancer: a critical appraisal of the present status.
Walther PJ
Semin Urol; 1993 Nov; 11(4):227-34. PubMed ID: 8290828
[No Abstract] [Full Text] [Related]
18. [Is down-staging of advanced bladder cancer by neoadjuvant chemotherapy possible?--MVEC protocol].
Hoch V; Noll F; Schreiter F
Urologe A; 1992 Jul; 31(4):243-6. PubMed ID: 1514212
[TBL] [Abstract][Full Text] [Related]
19. Systemic chemotherapy for muscle invasive bladder cancer.
Ondrus D; Hornák M; Bárdos A; Ondrus B
Neoplasma; 1994; 41(5):263-8. PubMed ID: 7854496
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) for infiltrating transitional cell carcinoma of the bladder.
Sternberg CN; Arena MG; Calabresi F; De Carli P; Platania A; Zeuli M; Giannarelli D; Cancrini A; Pansadoro V
Cancer; 1993 Sep; 72(6):1975-82. PubMed ID: 8364877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
